S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
OTCMKTS:EPGNY

Epigenomics - EPGNY Stock Forecast, Price & News

$2.39
0.00 (0.00%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.39
▼
$2.39
50-Day Range
$2.39
▼
$9.56
52-Week Range
$2.01
▼
$2.39
Volume
N/A
Average Volume
100 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
EPGNY stock logo

About Epigenomics (OTCMKTS:EPGNY) Stock

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Receive EPGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epigenomics and its competitors with MarketBeat's FREE daily newsletter.

EPGNY Stock News Headlines

January 27, 2023 | uk.finance.yahoo.com
Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski
January 27, 2023 | markets.businessinsider.com
EQS-News: Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski
February 3, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 23, 2022 | markets.businessinsider.com
EQS-News: Pareto Securities AS publishes buy recommendation for Epigenomics AG share
December 21, 2022 | markets.businessinsider.com
EQS-Adhoc: Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022
December 14, 2022 | markets.businessinsider.com
EQS-Adhoc: Epigenomics Releases Performance Data on Next Generation Test
December 14, 2022 | uk.finance.yahoo.com
Epigenomics Releases Performance Data on Next Generation Test
December 14, 2022 | markets.businessinsider.com
EQS-News: Epigenomics Releases Performance Data on Next Generation Test
February 3, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 14, 2022 | markets.businessinsider.com
EQS-News: Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test
September 19, 2022 | markets.businessinsider.com
EQS-Adhoc: Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs
September 19, 2022 | uk.finance.yahoo.com
Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test
September 19, 2022 | markets.businessinsider.com
EQS-News: Epigenomics Initiates prospective multi-center clinical trial for Next-Generation blood-based colorectal cancer test
September 9, 2022 | markets.businessinsider.com
DGAP-Adhoc: Epigenomics AG: Capital reduction planned at a ratio of 4 : 1
August 15, 2022 | uk.finance.yahoo.com
Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG
August 15, 2022 | markets.businessinsider.com
DGAP-News: Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG
August 10, 2022 | markets.businessinsider.com
DGAP-News: Epigenomics AG Reports Financial Results for the First Six Months of 2022
May 11, 2022 | uk.finance.yahoo.com
Epigenomics AG Reports Financial Results for the First Quarter of 2022
May 11, 2022 | markets.businessinsider.com
DGAP-News: Epigenomics AG Reports Financial Results for the First Quarter of 2022
March 30, 2022 | marketwatch.com
Global Personalized Medicine and Epigenomics Market 2022 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2028
March 24, 2022 | markets.businessinsider.com
DGAP-News: Epigenomics AG Reports Financial Results for Fiscal Year 2021
January 14, 2022 | nasdaq.com
EPGNY After-Hours Quotes
January 6, 2022 | nasdaq.com
EPGNY Real-Time Quotes
November 10, 2021 | markets.businessinsider.com
DGAP-News: Epigenomics AG publishes financial results for the first nine months 2021
September 13, 2021 | uk.finance.yahoo.com
Epigenomics AG places maximum number of mandatory convertible bonds with a total volume of EUR 16.5 million
August 17, 2021 | uk.finance.yahoo.com
Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance
December 22, 2020 | finance.yahoo.com
Sonim Announces Software Development Relationship with Coforge
See More Headlines
Receive EPGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epigenomics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:EPGNY
CUSIP
N/A
CIK
N/A
Web
www.epigenomics.com
Phone
(493) 024-3450
Fax
N/A
Employees
32
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Gregory K. Hamilton (Age 52)
    CEO & Member of the Exec. Board
    Comp: $828.44k
  • Dr. Andrew A. Lukowiak Ph.D. (Age 50)
    Pres & Chief Scientific Officer
    Comp: $387.44k
  • Mr. Jens Ravens (Age 52)
    CFO & Member of Exec. Board
  • Frederic Hilke
    Investor Relations Officer
  • Dr. Noel Thomas Doheny
    Chief Exec. Officer of Epigenomics Inc.

Key Competitors

View All Competitors













EPGNY Stock - Frequently Asked Questions

How have EPGNY shares performed in 2023?

Epigenomics' stock was trading at $9.56 at the start of the year. Since then, EPGNY shares have decreased by 75.0% and is now trading at $2.39.
View the best growth stocks for 2023 here.

What is Epigenomics' stock symbol?

Epigenomics trades on the OTCMKTS under the ticker symbol "EPGNY."

How do I buy shares of Epigenomics?

Shares of EPGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Epigenomics' stock price today?

One share of EPGNY stock can currently be purchased for approximately $2.39.

How can I contact Epigenomics?

Epigenomics' mailing address is Geneststrasse 5, Berlin, Berlin 10829. The official website for the company is www.epigenomics.com. The company can be reached via phone at (493) 024-3450.

This page (OTCMKTS:EPGNY) was last updated on 2/3/2023 by MarketBeat.com Staff